<DOC>
	<DOCNO>NCT02681328</DOCNO>
	<brief_summary>The purpose study compare performance Afirma GEC ThyroSeq v.2 indeterminate thyroid nodule determine test allow patient avoid unnecessary surgery preserve quality life .</brief_summary>
	<brief_title>Randomized Trial Comparing Performance Molecular Markers Indeterminate Thyroid Nodules</brief_title>
	<detailed_description>1 . All patient undergo thyroid FNA within UCLA Health System randomize time FNA single molecular test ( GEC ThyroSeq v.2 ) . 2 . During FNA , sample collect molecular test . 3 . If cytology result indeterminate ( Bethesda categories 3 4 ) , molecular test reflexively send . 4 . We help patient indeterminate thyroid nodule establish care endocrinologist , already one . The physician make treatment recommendation use best practice incorporate result molecular test . We anticipate patient positive molecular test undergo surgery , majority negative test surveil . 5 . Patients undergo surgery histopathologic evaluation thyroid , determine whether index thyroid nodule benign malignant . 6 . Patients undergo surgery followup ultrasound 6 12 month , sooner discretion treat physician . 7 . We assess thyroid-specific quality life baseline ( follow initial diagnosis indeterminate thyroid nodule ) followup ( 6 12 month ) use short version Thyroid-Related Patient-Reported Outcome .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Nodule</mesh_term>
	<criteria>Patients thyroid nodule thyroid biopsy perform UCLA health eligible study consent agree participate . Patients indeterminate FNA biopsy result ( Bethesda category 3 4 ) enrol study agree participate . Patients indeterminate biopsy result ( either patient benign , insufficient , malignant result ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>